LONDON/TOKYO (Reuters) - GlaxoSmithKline has raised its bet on a promising drug for HIV/AIDS by redrawing a deal with Japan's Shionogi, giving it a much bigger economic interest in the new product. Dolutegravir, a once-daily drug that has performed strongly in clinical trials, is seen by analysts as a potential multibillion-dollar-a-year seller and a strong competitor to treatments from market leader Gilead Sciences. ...



More...

From Yahoo Health.